8 years ago

Glide Technologies Raises £3.2 Million for Needle-Free Drug Delivery

  • Glide Technologies, a UK-based pharmaceutical development and device company, has secured £3.2 million in funding

  • Existing investors Invesco Perpetual, Oxford Technology Venture Capital Trusts, Oxford Capital Partners, and Hygea VCT participated in the round

  • The company will use the funds to complete Phase I clinical trials of its novel solid dose formulation of teriparatide (parathyroid hormone)

  • Teriparatide is approved for use in the treatment of osteoporosis and accounts for global sales of over $1.3 billion.

      • ProblemHealthcare

      "Glide Technologies aims to overcome the discomfort and fear associated with traditional needle injections by developing a needle-free injector for administering solid dose formulations of therapeutics and vaccines."

      Solution

      "The company has developed the Glide SDI®, a proprietary needle-free injector, which is designed to deliver solid dose formulations of therapeutics and vaccines, offering a more comfortable and convenient method of drug administration."

      Covered on